sturlimogene erparepvec

AXP000078.1 · Oncolytic virus

Platform
HSV-1 (RH018A strain, ICP34.5- ICP47-)
Originator
Replimune
Sponsor
Replimune

Names

NameTypeSource
sturlimogene erparepvecpreferred name, INNcurator, ncit
RP2 ambiguouscodencit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
RH018A
Replication
conditionally replicating
Modifications
RL1 (ICP34.5) and US12 (ICP47) deleted
Transgenes
CSF2, GALV-GP R-, anti-CTLA-4 antibody
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C176748
FDA UNII
53Z5E7R5KD

Approvals

No regulatory approval recorded.

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07059611Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal AdenocarcinomaNot yet recruitingPhase 22027-04-012027-11-0134Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
NCT07218692RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyWithdrawnPhase 22026-08-112027-08-110Advanced Clear Cell Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
NCT06581406A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaRecruitingPhase 2/32024-12-172030-01280Metastatic Uveal Melanoma
NCT05733598Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCRecruitingPhase 22024-08-012027-12-0160Biliary Tract Cancer; Hepatocellular Carcinoma
NCT05733611RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCTerminatedPhase 22023-06-292025-08-185MSS; Refractory Metastatic Colorectal Cancer; pMMR
NCT04336241Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsActive not recruitingPhase 12019-10-172026-10-3136Cancer

Recent changes

No changes recorded in its trials yet.

Notes

RP2: the RP1 backbone with an added anti-CTLA-4 antibody-like molecule. Dosed with and without nivolumab; a phase 2 in colorectal cancer (NCT05733611) was terminated.

How to cite

sturlimogene erparepvec (AXP000078.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000078.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.